| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Neuronetics (NASDAQ:STIM) lowers FY2025 sales outlook from $149.000 million-$155.000 million to $147.000 million-$150.000 milli...
Neuronetics (NASDAQ:STIM) sees Q4 sales of $40.000 million-$43.000 million vs $43.057 million analyst estimate.
Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.10)...
Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that imp...
Canaccord Genuity analyst William Plovanic maintains Neuronetics (NASDAQ:STIM) with a Buy and lowers the price target from $...
Neuronetics (NASDAQ:STIM) affirms FY2025 sales outlook from $149.000 million-$155.000 million to $149.000 million-$155.000 mill...